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Prevalence, associations, and adequacy of treatment of 
major depression in patients with cancer: a cross-sectional 
analysis of routinely collected clinical data
Jane Walker*, Christian Holm Hansen*, Paul Martin, Stefan Symeonides, Ravi Ramessur, Gordon Murray, Michael Sharpe
Summary
Background Major depression is an important complication of cancer. However, reliable data are lacking for the prevalence 
of depression in patients with cancer in diﬀ erent primary sites, the association of depression with demographic and 
clinical variables within cancer groupings, and the proportion of depressed patients with cancer receiving potentially 
eﬀ ective treatment for depression. We investigated these questions with data from a large representative clinical sample.
Methods We analysed data from patients with breast, lung, colorectal, genitourinary, or gynaecological cancer who had 
participated in routine screening for depression in cancer clinics in Scotland, UK between May 12, 2008, and Aug 24, 2011. 
Depression screening was done in two stages (ﬁ rst, Hospital Anxiety and Depression Scale; then, major depression section 
of the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition). Data for 
depression status were linked with demographic and clinical data obtained from the Scottish National Cancer Registry.
Findings We analysed data for 21 151 patients. The prevalence of major depression was highest in patients with lung 
cancer (13·1%, 95% CI 11·9–14·2%), followed by gynaecological cancer (10·9%, 9·8–12·1), breast cancer (9·3%, 
8·7–10·0), colorectal cancer (7·0%, 6·1–8·0), and genitourinary cancer (5·6%, 4·5–6·7). Within these cancer 
groupings, a diagnosis of major depression was more likely in patients who were younger, had worse social deprivation 
scores, and, for lung cancer and colorectal cancer, female patients. 1130 (73%) of 1538 patients with depression and 
complete patient-reported treatment data were not receiving potentially eﬀ ective treatment.
Interpretation Major depression is common in patients attending cancer clinics and most goes untreated. A pressing 
need exists to improve the management of major depression for patients attending specialist cancer services.
Funding Cancer Research UK and Chief Scientist Oﬃ  ce of the Scottish Government.
Introduction
Major depression is a leading cause of disability world-
wide and when comorbid with a chronic disease it is 
associated with reduced quality of life and increased 
health-care costs.1–3 Cancer is becoming a chronic 
disease for a rapidly increasing number of people; in the 
UK alone more than 3 million people are expected to 
have a diagnosis of cancer by 2030.4 Patients with cancer 
and comorbid depression have worse anxiety, pain, 
fatigue, and functioning than do other patients with 
cancer.5–7 They are also more likely to have suicidal 
thoughts, and to have more diﬃ  culties with adherence 
to cancer treatments.8,9
Consequently, better methods of identiﬁ cation and 
treatment of depression in patients attending cancer 
services are needed: the English Department of Health, 
the UK National Institute for Health and Care Excellence, 
and the US Institute of Medicine have all called for 
eﬀ ective management of depression that is integrated 
into patients’ cancer care.10–13 The American College of 
Surgeons’ Commission on Cancer14 requires that, from 
2015, cancer centres in the USA must screen patients for 
psychosocial distress (which includes depression).
To improve care, we need to know how many patients 
attending cancer services have major depression, which 
patients are most likely to be depressed, and what 
proportion of patients receive adequate treatment for 
their depression. However, we lack robust data to answer 
all of these basic questions. Two recent meta-analyses 
have reported pooled prevalence (for patients with all 
types of cancer) of interview-diagnosed depression of 
16% and 13%.15,16 However, these ﬁ ndings are substantially 
limited by (1) the questionable assumption that the 
prevalence of major depression is similar across diﬀ erent 
patient subgroups and consequently that a pooled 
estimate is clinically meaningful, (2) the use of various 
diagnostic criteria, interview types, and interviewer 
expertise for deﬁ ning and identifying depression, and (3) 
the typically small, non-representative samples and 
generally poor methodological quality of the primary 
studies. These limitations are shown by the wide range 
(1–77%)15 of prevalence reported in the individual studies. 
A systematic review17 that addressed study quality found 
that only 15 publications met basic methodological 
standards; even these higher quality studies did not 
provide reliable data for the prevalence of depression in 
patients with diﬀ erent primary cancer sites or useful 
estimates of the proportion of patients with cancer and 
comorbid depression receiving potentially eﬀ ective 
treatment.
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We assessed in a large representative sample (1) the 
prevalence of major depression in patients with common 
cancers (breast, lung, colorectal, genitourinary, and 
gynaecological), (2) the association of major depression 
with demographic and clinical variables within each of 
these cancer groupings, and (3) the proportion of patients 
with major depression who were receiving potentially 
eﬀ ective treatment.
Methods
Study design
We did a cross-sectional analysis of routine clinical data 
provided by a large-scale outpatient depression screening 
service linked with demographic and clinical data. The 
data relate to patients who attended outpatient clinics of 
the Edinburgh, Glasgow, and Dundee National Health 
Service cancer centres in Scotland, UK. Each centre 
provides a full range of diagnostic and treatment services 
in large urban teaching hospitals and has outreach 
clinics in the smaller hospitals of surrounding towns. 
The centres together serve a geographically deﬁ ned area 
of roughly 4 million people and provide specialist care 
for the vast majority of patients in this region diagnosed 
with cancer.
We included a patient’s data if they had attended an 
outpatient oncology consultation (in a central or outreach 
cancer clinic) between May 12, 2008 and Aug 24, 2011; if 
they had participated in the routine screening service for 
depression that operated in the three centres; if we could 
obtain matched demographic and clinical data from the 
Scottish National Cancer Registry; if they had given consent 
for their relevant clinical data to be used for research; and if 
they had a primary breast, lung, colorectal, genitourinary, 
or gynaecological cancer. We chose these cancer groupings 
because they are the most common, they often form the 
basis for multidisciplinary cancer care (therefore the 
prevalence of depression in each group is clinically useful), 
and the number of patients within each grouping was 
suﬃ  cient to estimate prevalence with acceptable accuracy.
The study was approved by the South East Scotland 
Research Ethics Committee, the NHS Scotland Caldicott 
Guardian Forum, and the NHS Scotland Privacy Advisory 
Committee.
Procedures
The screening service for depression was oﬀ ered to 
everyone who attended the clinics and used a 
conventional two-stage procedure.18 In the ﬁ rst stage, 
patients rated their symptoms over the preceding week 
on the Hospital Anxiety and Depression Scale (HADS), 
which has 14 items, each of which is scored from zero 
to three.19 This was done with the help of a screening 
assistant, using touchscreen computers or paper 
questionnaires, while the patient was waiting in the 
cancer clinic to see their oncologist (if the patient did 
not complete the HADS, the reason was recorded). The 
screening database automatically calculated each 
patient’s total HADS score and highlighted those 
patients who needed a second stage assessment.
In the second stage, patients with a high HADS score 
(total score ≥15; a cut-oﬀ  which has been reported to oﬀ er 
good sensitivity and speciﬁ city for major depression in 
patients with cancer with a misclassiﬁ cation rate of only 
0·01)20 were telephoned at home (usually within several 
days of clinic attendance) and given a brief semi-
structured clinical interview (reasons for non-completion 
of this interview were recorded). The interview consisted 
of the depression section of the Structured Clinical 
Interview for the Diagnostic and Statistical Manual of 
Mental Disorders, 4th Edition (SCID)21 to establish 
whether the patient met criteria for major depression.22 
Telephone SCID interviews have good agreement with 
face-to-face interviews.23 Patients diagnosed with major 
depression were asked additional questions about the 
treatments that they were receiving for depression. The 
patient’s primary care physician and oncologist were 
then told that their patient had depression.
The timing of screening for depression varied by 
cancer clinic (some oncologists preferred that screening 
was only oﬀ ered to patients attending return appoint-
ments). The screening service was delivered by a team of 
screening assistants (psychology graduates and general 
nurses), trained and supervised by consultation-liaison 
psychiatrists. All clinical and administrative data, 
including telephone interviews (which were digitally 
recorded with patients’ permission), were stored on a 
secure database.
A diagnosis of major depression was made using the 
standard inclusive approach (all relevant symptoms 
counted towards the diagnosis of depression without 
attempting to establish whether they should be 
attributed to depression or to cancer); this is the most 
reliable method and does not signiﬁ cantly overestimate 
Figure 1: Study proﬁ le
*The patient was taken into their oncology appointment before they were able 
to complete the Hospital Anxiety and Depression Scale.
26 570 patients attended 
clinic appointments 
5419 excluded from analysis
 4567 not screened
  2097 stage 1 screening not started or interrupted*
  877 clinician advised not to screen
  557 declined screening
  309 too unwell for screening
  300 other
  216 administrative error in clinic
  211 communication or cognitive diﬃculties
 852 screened but data not included
  689 no matched data found in cancer registry
  163 no consent to use data for research  
21 151 patients included
in analysis 
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depression in the medically ill.24 To minimise the 
misdiagnosis of major depression in patients who might 
have been more properly diagnosed with an adjustment 
disorder, major depression was only diagnosed if the 
patient described relevant symptoms of at least 4 weeks’ 
duration. If they reported symptoms between 2 weeks 
(the usual minimum duration required for a diagnosis 
of major depression) and 4 weeks, the patient was re-
interviewed 2 weeks later. The screening service used 
the following procedures to ensure the validity of the 
diagnosis of major depression: (1) screening assistants 
were trained for 4 weeks by consultation-liaison 
psychiatrists with expertise in SCID interviewing; 
(2) they were then required to show competence by 
completion of 20 well done interviews resulting in 
accurate diagnoses; and (3) their ongoing competence 
was ensured by weekly supervision by a psychiatrist 
informed by review of recordings of at least 10% of their 
telephone interviews.
Patients with major depression at interview were 
asked whether they were receiving any drug treatment 
for depression and whether they were visiting a mental 
health professional (psychiatrist or psychologist). The 
screening team used additional questions to clarify 
patients’ responses where necessary and noted anti-
depressant drug names and doses.
We obtained data for the patients’ demographic and 
clinical characteristics from the NHS Scotland Cancer 
Registry. The Registry systematically collects information 
from hospitals throughout Scotland for all recorded 
cases of cancer. The demographic data obtained included 
data for sex, age, area of residence (urban, small town, 
rural) and social deprivation score (calculated with the 
Scottish Index of Multiple Deprivation, based on area of 
residence; appendix p 2). The clinical data included 
primary cancer grouping (appendix pp 3–5), time since 
diagnosis, whether initial cancer treatment had been 
started in the preceding 6 months, and initial treatment 
objective (curative or palliative), as supplied to the 
Registry by the relevant hospital.
The data manager for the screening service identiﬁ ed a 
single depression screening episode for each patient and 
extracted the relevant data from the screening database. 
If patients were screened for depression more than once 
Patients (N=21 151)
Sex
Women 15 112 (71%)
Men 6039 (29%)
Age (years)
Mean (SD) 64·4 (11·9)
Range 19–100
Age groups (years)
<50 2521 (12%)
50–59 4104 (19%)
60–69 6820 (32%)
≥70 7706 (36%)
Area of residence
Urban 16 689 (79%)
Small town 2001 (9%)
Rural 2461 (12%)
SIMD quintile score*
1 4572 (22%)
2 4259 (20%)
3 3781 (18%)
4 3731 (18%)
5 4808 (23%)
Primary cancer
Breast 8461 (40%)
Lung 4316 (20%)
Colorectal 3355 (16%)
Gynaecological 3010 (14%)
Genitourinary 2009 (9%)
Clinic appointment type
First appointment 3117 (15%)
Return appointment 17 760 (84%)
Missing data 274 (1%)
Time since cancer diagnosis (years)
Median (IQR) 1·0 (0·3–3·2)
Recently started initial cancer treatment†
No 13 325 (63%)
Yes 7462 (35%)
Missing data 364 (2%)
First treatment objective
Curative 13 127 (62%)
Palliative 5413 (26%)
Missing data 2611 (12%)
Data are number (%) unless otherwise stated. SIMD=Scottish Index of Multiple 
Deprivation. *1=most deprived, 5=least deprived. †Any of chemotherapy, 
radiotherapy, or surgery started in the preceding 6 months. 
Table 1: Characteristics of patients See Online for appendix
Figure 2: Prevalence of major depression in patients with cancer
Error bars show 95% CIs.
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during the study period, the data extracted were those 
relating to the earliest of their clinic appointments. These 
data were then linked with corresponding data in the 
cancer registry. To ensure data security and conﬁ dentiality 
the screening dataset was sent to the Information 
Services Division of NHS Scotland for linking using 
unique patient identiﬁ cation numbers (Community 
Health Index numbers) and dates of birth. All identifying 
data were then removed in a one-way linkage to produce 
the anonymised dataset that was used for analysis.
Statistical analysis
We estimated the point prevalence of major depression 
for patients in each of the primary cancer groupings 
(breast, lung, colorectal, genitourinary, and gynaecological). 
1145 (21%) of 5510 patients who had scored high on the 
HADS had missing data for depression diagnosis because 
of non-completion of the clinical interview; to assume that 
such patients were not depressed or to simply omit them 
from the analysis could have resulted in biased estimates. 
We therefore handled these incomplete data with multiple 
imputation techniques (for full details of the imputation, 
see appendix p 2) to estimate the number (and therefore 
proportion) of screened patients who had major depression 
in each cancer grouping. We did sensitivity analyses to 
assess the robustness of our ﬁ ndings under alternative 
scenarios for missing data.
We used multivariable logistic regressions to assess the 
independent associations of major depression with 
patients’ demographic and clinical characteristics, within 
each cancer grouping.
We also calculated the proportion of patients with 
depression in the whole sample who were receiving 
potentially eﬀ ective treatment for depression. We deﬁ ned 
potentially eﬀ ective treatment as presently receiving an 
antidepressant drug at a minimal eﬀ ective or higher 
dose (appendix p 6)25 or presently visiting a mental health 
professional (psychiatrist or psychologist). These data 
were from patients who had been diagnosed with major 
depression in the clinical interview and had given 
information about the treatment that they were receiving 
(ie, we did not impute missing data for this part of the 
analysis). We also analysed the associations of treatment 
receipt with sex, age, social deprivation, and cancer 
grouping in a multivariable logistic regression.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
JW, CHH, PM, GM and MS had full access to data collected 
for the study and all authors had ﬁ nal responsibility for the 
decision to submit the report for publication.
Results
26 570 patients had attended cancer clinic appointments 
during the time period for which screening data were 
obtained. We analysed data for 21 151 (80%) of these 
patients. The main reason that patients were excluded 
from the analysis was failure to participate in depression 
screening; most commonly because the patient’s oncology 
appointment had begun before they could complete the 
HADS (ﬁ gure 1).
Most participants were women and their mean age was 
64 years (table 1). Most were attending return (rather 
than ﬁ rst) appointments at the oncology clinic. Median 
time from cancer diagnosis to screening for depression 
was 1 year. 5510 (26%) of 21 151 screened patients had a 
HADS score of 15 or more. Of these patients, 4365 (79%) 
completed a SCID depression interview (the main reason 
for non-completion of an interview was that the patient 
declined or could not be contacted; n=701); we imputed 
data for depression diagnosis for the remainder.
The prevalence of major depression was highest in 
patients with lung cancer (13·1%, 95% CI 11·9–14·2) 
followed by gynaecological cancer (10·9%, 9·8–12·1), 
breast cancer (9·3%, 8·7–10·0), colorectal cancer (7·0%, 
6·1–8·0), and genitourinary cancer (5·6%, 4·5–6·7; 
ﬁ gure 2). In sensitivity analyses to assess the robustness of 
our ﬁ ndings under alternative scenarios for missing data, 
prevalence estimates diﬀ ered from those of the main 
analysis by less than 2 percentage points, there was little 
variation in the absolute diﬀ erences between the ﬁ ve 
prevalence estimates, and the order of estimates remained 
unchanged (data not shown).
In all ﬁ ve cancer groupings, depression was signiﬁ cantly 
more common in younger patients than in older patients 
and in those with worse than in those with better social 
deprivation scores (table 2). In the cancer groupings for 
which we were able to analyse the independent associations 
of sex (lung, genitourinary, and colorectal), depression was 
signiﬁ cantly more common in female patients than in 
male patients for lung cancer and colorectal cancer, with a 
non-signiﬁ cant trend in this direction for patients with 
genitourinary cancer. Depression was not independently 
associated with urban or rural residence. Time since cancer 
diagnosis was not associated with depression except for 
patients with gynaecological cancer (table 2). Nor was 
depression associated with whether the patient had started 
initial cancer treatment (chemotherapy, radiotherapy, or 
surgery) in the 6 months preceding screening, or with 
stated initial treatment objective (palliative or curative) in 
any of the ﬁ ve groupings. Estimates of these associations 
with major depression diﬀ ered negligibly across our 
sensitivity analyses (data not shown).
Of the 1599 patients diagnosed with major depression at 
interview, we had complete patient-reported treatment data 
for 1538 (96%). Most (n=1130, 73%) of these patients were 
not receiving any potentially eﬀ ective treatment for 
depression; less than a quarter were receiving an anti-
depressant drug at a minimal eﬀ ective dose or higher and 
very few were visiting a mental health professional (ﬁ gure 3). 
Patients with depression were more likely to be receiving 
treatment if they were younger and if they were female 
(table 3). Patients with breast cancer were most likely to 
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receive treatment for depression (32%) and those with lung 
cancer were least likely to receive treatment (19%).
Discussion
The prevalence of major depression was highest in 
patients with lung cancer and lowest in those with 
genitourinary cancer. The variation between cancer 
groupings shows the limitations of prevalence estimates 
based on pooled samples. Within the cancer groupings, 
patients who were younger, had worse social deprivation 
scores, and (for cancers that aﬀ ected both sexes) those 
who were female were more likely to have major 
depression; consistent with ﬁ ndings in the general 
population.26 Of the patients diagnosed with major 
depression, most were not in receipt of any potentially 
eﬀ ective treatment.
It was notable that patients who had been living with a 
cancer diagnosis for more than a year were just as likely 
to have depression as were those diagnosed more 
recently, and that patients who had received initial 
curative treatment were just as likely to have depression 
as were those who had been treated with palliative intent.
Our ﬁ ndings suggest that major depression is sub-
stantially more common in people with cancer than in 
the general population. Direct comparisons between 
these ﬁ ndings and those from the general population 
are made diﬃ  cult by the varying diagnostic criteria, 
time periods, and interview methods that have been 
used in published population surveys. However, the 
prevalence of depression we recorded in all cancer 
group ings was more than twice the estimated point 
prevalence reported in the general population (2%)27and 
higher than the estimated 12 month prevalence in the 
general population (4–5%).26,28
Perhaps our most important ﬁ nding was that most 
cancer outpatients with depression were not in receipt of 
potentially eﬀ ective treatment for their depression. 
Although under-treatment of major depression has 
previously been reported for the general population, and 
for those who self-reported a diagnosis of cancer when 
asked in a survey, the under-treatment of patients attending 
specialist cancer services is especially concerning.27,29–32
This study is the ﬁ rst to report the prevalence of major 
depression in patients with cancer with data from large-
scale screening (panel). It has several strengths. First, 
the size of the sample was more than twice that of the 
total number of patients included in each of two meta-
analyses (8747 and 10 071 patients);15,16 second, the use of 
screening to obtain a representative sample; third, the 
use of rigorous interview-based diagnoses of depression 
(rather than questionnaires, which are likely to have a 
high false-positive rate) made according to standard 
diagnostic criteria by trained interviewers; fourth, 
cancer diagnoses made by specialist clinicians; ﬁ fth, the 
use of interviews to establish the treatments for 
depression actually received by patients.
The study also had limitations. First, patients had 
attended publicly funded specialist cancer clinics in 
Scotland. Our ﬁ ndings might not therefore generalise 
to other populations (such as for patients who were 
diagnosed many years ago and who no longer attend 
clinics) or to cancer patients in all health-care settings. 
However, they are likely to have relevance to all cancer 
centres that treat common cancers. Second, not all 
Figure 3: Treatments received by outpatients with cancer and major depression
Proportions based on 1538 patients diagnosed with major depression at clinical interview and with complete 
treatment data. Antidepressant drugs were amitriptyline, citalopram, clomipramine, dosulepin, doxepin, 
duloxetine, escitalopram, ﬂ uoxetine, ﬂ upentixol, ﬂ uvoxamine, imipramine, lofepramine, mirtazapine, 
nortriptyline, paroxetine, phenelzine, reboxetine, sertraline, trazodone, trimipramine, venlafaxine.
1130 not receiving 
any treatment
(73%)
(22%)
370 taking antidepressant 
drugs (24%)
74 seeing a mental health 
professional (5%)3%
2%
2%
In receipt of 
treatment*(n=408)
Not in receipt of 
treatment (n=1130)
Adjusted odds ratio 
(95% CI)
p value
Sex 0·0004
Men 54 (18%) 251 (82%) 1
Women 354 (29%) 879 (71%) 2·22 (1·43–3·45)
Age (years) <0·0001
<50 105 (35%) 199 (65%) 1
51–59 146 (31%) 318 (69%) 0·91 (0·67–1·25)
60–69 120 (25%) 369 (75%) 0·68 (0·49–0·94)
≥70 37 (13%) 244 (87%) 0·33 (0·22–0·51)
SIMD score 0·489
1 153 (29%) 372 (71%) 1·37 (0·92–2·03)
2 92 (25%) 269 (75%) 1·14 (0·75–1·72)
3 68 (26%) 196 (74%) 1·13 (0·73–1·76)
4 49 (26%) 142 (74%) 1·10 (0·69–1·77)
5 46 (23%) 151 (77%) 1
Primary cancer 
grouping†
0·0048
Colorectal 44 (25%) 133 (75%) 1
Breast 198 (32%) 429 (68%) 0·93 (0·61–1·42)
Genitourinary 25 (30%) 57 (70%) 2·16 (1·13–4·13)
Gynaecological 66 (25%) 195 (75%) 0·68 (0·42–1·10)
Lung 75 (19%) 316 (81%) 0·75 (0·48–1·17)
Data are n (%). Of 1599 patients diagnosed with major depression at interview, 61 had incomplete treatment data. 
*Presently receiving an antidepressant drug at a minimal eﬀ ective dose or higher (according to dose guidance) or 
seeing a mental health professional (psychiatrist or psychologist). †The associations of sex and cancer site were heavily 
confounded (eg, treatment receipt was highest among patients with breast cancer despite the moderate adjusted 
eﬀ ect size). Odds ratios are fully adjusted and estimate independent eﬀ ects (eg, among participants with otherwise 
similar characteristics, there was no evidence that patients with breast cancer are more likely to receive treatment). 
 Table 3: Independent associations of receipt of potentially eﬀ ective treatment for major depression
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clinic patients were screened for depression and we 
could not characterise those who were not (because they 
had not had the opportunity to give consent for their 
data to be used). However, most patients did participate, 
and the main reason for not doing so was simply 
insuﬃ  cient time to complete the HADS screening 
before seeing the oncologist, which is unlikely to be 
substantially aﬀ ected by depression. Third, because data 
for depression diagnosis were only available for patients 
who scored highly on the initial screening questionnaire, 
some cases might have been missed at this ﬁ rst stage. 
However, the misclassiﬁ cation rate of the HADS cutoﬀ  
score used by the screening service is very low.20 Fourth, 
we did not have diagnostic interview data for all patients 
who scored high on the HADS at stage one of screening. 
We did, however, use multiple imputation and sensitivity 
analyses to handle these missing data to reduce and 
assess the potential bias in estimates and these results 
were robust. Fifth, the number of demographic and 
clinical variables that we assessed for an association 
with depression was limited by the data collected 
routinely by the screening service and by the cancer 
registry. Our ﬁ ndings should therefore be qualiﬁ ed by 
the possibility of unmeasured confounding variables. 
Finally, our assessment of treatment receipt relied on 
questions asked by the screening team. Although the 
interviewers were trained to interpret and probe answers 
to these questions and the accuracy of self-reported use 
of mental health services has been reported to be good,33 
some patients might not have reported their treatment 
accurately, might have been oﬀ ered but declined 
treatment, or might have been receiving psychological 
treatment from other professionals.
These ﬁ ndings have several implications for clinical 
services. Major depression, although not ubiquitous 
among cancer outpatients, is common and therefore 
merits greater attention. Furthermore, its greater 
prevalence in patients with some cancer groupings, 
notably lung cancer, suggests where screening for 
depression will ﬁ nd the most cases. Finally, despite its 
adverse eﬀ ects on quality of life and adherence to 
treatment, depression in patients attending cancer 
clinics is inadequately managed at present. Systematic 
approaches to improving depression care for patients 
with cancer are urgently needed; we have described and 
evaluated one such approach.34,35
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